Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 407,958	$ 375,935	[1]
Marketable securities	39,813	0
Investments in equity securities	0	58,949	[1]
Receivables from licensing and collaboration agreements	660	1,751	[1]
Restricted cash	139,409	16,653	[1]
Prepaid expenses and other current assets	28,396	24,305	[1]
Total current assets	616,236	477,593	[1]
Investment in nonconsolidated entity	117,006	0
Property and equipment, net	9,840	11,816	[1]
Operating lease right-of-use assets	7,267	8,027	[1]
Intangible assets, net	25,123	26,319	[1]
Other assets	18,903	22,625	[1]
Total assets	794,375	546,380	[1]
Current liabilities:
Accounts payable	18,126	10,655	[1]
Accrued compensation and benefits	29,056	57,370	[1]
Accrued research and development liabilities	33,178	29,765	[1]
Operating lease liabilities, current portion	4,623	4,128	[1]
Deferred revenue, current portion	15,098	6,096	[1]
Accrued professional and other accrued liabilities	34,283	35,830	[1]
Total current liabilities	134,364	143,844	[1]
Term loan, net	435,447	446,445	[1]
Operating lease liabilities, net of current portion	7,059	8,981	[1]
Deferred revenue, net of current portion	16,961	3,727	[1]
Other long-term liabilities	485	5,634	[1]
Total liabilities	1,876,468	1,888,915	[1]
Commitments and contingencies (Note 8)
Redeemable convertible noncontrolling interests	(223)	478
Stockholders’ equity (deficit):
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 194,224,499 shares issued and 188,032,738 shares outstanding as of June 30, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023	194	181	[1]
Treasury stock, at cost; 6,191,761 shares as of June 30, 2024 and December 31, 2023	(275,000)	(275,000)	[1]
Additional paid-in capital	1,851,058	1,481,032	[1]
Accumulated other comprehensive income	(4)	31	[1]
Accumulated deficit	(2,669,173)	(2,560,501)	[1]
Total BridgeBio stockholders' deficit	(1,092,925)	(1,354,257)	[1]
Noncontrolling interests	11,055	11,244	[1]
Total stockholders' deficit	(1,081,870)	(1,343,013)	[1],[2]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	794,375	546,380	[1]
2029 Notes
Current liabilities:
Notes, net	737,882	736,905	[1]
2027 Notes
Current liabilities:
Notes, net	$ 544,270	$ 543,379	[1]

[1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date.

[2] The consolidated balances as of December 31, 2023 and 2022 are derived from the audited consolidated financial statements as of those dates.